

Amendment No. 1

Tender Ref No.: - BPPI/DRUG/RC-159/2021

[e- TENDER FOR SUPPLY OF DRUGS]

No.:BPPI/DRUG/RC-159/2021-01

Dated: 29/01/2021

Reference: Pre-Bid meeting held on 21st January 2021 at 11:00 AM in the premises of BPPI.

The following amendment in Tender Document is hereby authorized: -

Part- A

Sl. No.	Tender Clause/Reference	Query/Suggestion	Clarification/ Amendment
1.	3.ELIGIBILITY CRITERIA (TECHNICAL BID - COVER "A")	Prospective bidder has requested to consider Medium Scale Industries/ Firm under MSME criteria referring MSME notification New Delhi dated 26 th June 2020 issued by Ministry of Micro, Small and Medium Enterprises (MSME).	Tender condition prevails.
2.	4. M) Validity of Rate Contract	Prospective bidder has requested to amend the provision of rate contract validity from two year as mentioned in clause 4. M to One year with simultaneous amendment in the extension of bid up to 06 to 12 months for better & smooth supplies.	Tender condition prevails.
3.	19. Supply condition clause no. D) Sl. no. 3	One of the prospective bidders has requested to provide 60 days delivery period from the date of receipt of purchase order as against the tender provision of 45 days in clause 19.	Tender condition prevails.
4.	3. ELIGIBILITY CRITERIA (TECHNICAL BID - COVER "A")	One of the prospective bidders has requested to consider 02 years Market standing instead of 3 years asked in the tender document.	Tender condition prevails.
5.	15. ACCEPTANCE /REJECTION OF BIDS	Intending bidder has requested to award at least 50% quantity to L1 bidder as against the tender provision of "Minimum 30% quantity to L1 bidder and remaining among the bidder's subject to the matching of L1 price for quoted drugs at the discretion of BPPI".	Tender condition prevails.
6.	1.TENDERING SYSTEM: ii. c)	One of the prospective bidders has requested to accept the supplies/products with their brand name.	Tender has been called for the Generic drugs only. Tender condition prevails.

7.	25. LIQIDATED DAMAGES & OTHER PENALTIES	Prospective bidder has requested to get the clarification of MRP Fixation saying they will not be able to accept BPPI MRP lesser than bidders quoted price, secondly, they have requested to accept packing if damaged without levying any penalty say they can replace the packing. Further they have requested to reduce Liquidated Damage charges either 0.5% /Week or 0.5% /Month & Other Penalties	MRP fixation of drugs is as per BPPIs policy. For remaining Tender condition prevails.
8.	4.GENERAL CONDITIONS	Prospective bidder has requested to allow Importers to participate in the tender.	Tender condition prevails.
9.	1.TENDERING SYSTEM: ii. c)	Prospective bidder has requested i)To Accept Ticagrelor 90mg tablet manufactured overseas and marketed in India. ii)To modify the unit size, pack size, packing per carton (shipper pack) to 14's as against 10's in tender document.	Tender condition prevails.
10.	18. METHODOLOGY FOR PLACING ORDERS T), 20 and 24	Prospective bidder has requested to relax specific artwork on Primary & secondary packing and they have also requested to waive off the provision of 'deducting 1.5% of the supply value towards handling & testing charges.	Tender condition prevails.
11.	3. ELIGIBILITY CRITERIA (TECHNICAL BID - COVER "A"): I)	Prospective bidder has requested to reduce the annual average turnover for any three of the last four consecutive financial years not less than 25 Crores (Twenty-Five crore) to minimum total turnover Rs. 25 crore any three of the last four consecutive financial years.	Tender condition prevails.

Part- B:

Sl. No.	Tender Clause/ Reference	Drug Code with Generic Name of the Drug, Drug Specification, Unit Size, Packing	Composition of the Drug in tender	Amendment
1.	Annexure-XII Clause 18(M) & BOQ	Prospective bidder has requested to accept DC-2 Aceclofenac Tablets IP 100 mg in Uncoated form as against Film coated tablet in the tender	Each film-coated tablet contains: Aceclofenac Tablets IP 100 mg	Tender condition prevails.
2.	Annexure-XII Clause 18(M) & BOQ	Prospective bidder has requested to accept DC-144 Metformin Hydrochloride Sustained Release	Each film-coated sustained release tablet contains:	Tender condition prevails.

		Tablets IP 1000 mg as Uncoated form as against Film coated tablet in the tender	Metformin Hydrochloride IP 1000mg	
3.	Annexure-XII Clause 18(M) & BOQ	Prospective bidder has requested to accept DC-367 Voglibose Tablets IP 0.3 mg as Uncoated Tablet form as against Film coated tablet in the tender	Each Film coated tablet contains: Voglibose IP 0.3mg	Tender condition prevails.
4.	Annexure-XII Clause 18(M) & BOQ	Prospective bidder has requested to accept DC-371 Voglibose Tablets IP 0.2 mg as Uncoated Tablet as against Film coated tablet in the tender	Each Film coated tablet contains: Voglibose IP 0.2mg	Tender condition prevails.
5.	Annexure-XII Clause 18(M) & BOQ	Prospective bidder has requested to change the dosage form of DC-598 from Tablet to Capsule	Each Film coated tablet contains: Pregabalin IP 75mg Methylcobalamin IP 750mcg	Tender condition prevails.
6.	Annexure-XII Clause 18(M) & BOQ	Prospective bidder has requested to change strength of DC-685 Itopride Hydrochloride 15mg (as sustained release pellets) to Itopride Hydrochloride 150mg	Each hard gelatin capsule contains: Pantoprazole Sodium IP equivalent to Pantoprazole 40mg (as enteric coated pellets) Itopride Hydrochloride 15mg (as sustained release pellets)	Each hard gelatin capsule contains: Pantoprazole Sodium IP equivalent to Pantoprazole 40mg (as enteric coated pellets) Itopride Hydrochloride 150mg (as sustained release pellets)
7.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to modify the DC -181as Each 5ml contains: Cyproheptadine Hydrochloride IP 2mg Tricholine Citrate 275mg Sorbitol (70%) Non-Crystallising IP 2gm Flavoured Syrup base q. s.	Each 5ml contains: Cyproheptadine Hydrochloride IP 2mg Tricholine Citrate 275mg	Each 5ml contains: Cyproheptadine Hydrochloride IP 2mg Tricholine Citrate 275mg Sorbitol (70%) Non-Crystallising IP 2gm Flavoured Syrup base q. s.
8.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to modify the DC-1454 as Each 5ml contains: Terbutaline Sulphate IP 1.25mg Ambroxol Hydrochloride IP 15mg Guaiphenesin IP 50mg Flavoured Menthol base q. s.	Each 5ml contains: Terbutaline Sulphate 1.25mg Ambroxol 30mg Guaifensin 50mg Menthol 2.5mg	Each 5ml contains: Terbutaline Sulphate IP 1.25mg Ambroxol Hydrochloride IP 15mg Guaiphenesin IP 50mg Flavoured Menthol base q. s.
9.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to amend DC-558 as AZELASTINE HCL 140 mcg + FLUTICASONE	Each Spray delivers: Fluticasone Furoate 27.5 mcg Azelastine Hydrochloride 140 mcg	Each Spray delivers: Fluticasone Furoate 27.5 mcg Azelastine Hydrochloride 140 mcg

		PROPIONATE 27.5 mcg 70 MDI Pack Size		70 MDI Pack Size
10.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to amend DC-560 as Fluticasone Propionate Nasal Spray IP 50 mcg 100 MDI Pack Size	Each spray delivers: Fluticasone Propionate IP 50 mcg	Each spray delivers: Fluticasone Propionate IP 50 mcg 100 MDI Pack Size
11.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to change DC-16 as Pack size 10x10 and unit size 10's	Each film-coated tablet contains: Ibuprofen IP 400mg, Unit size 15's and Pack size 15's X 10	Tender condition prevails.
12.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to change DC- 224 as Pack size 10x10 and unit size 10's	Each Uncoated tablet contain: Folic Acid IP 5 mg Unit size 15's and Pack size 15's X 10	Tender condition prevails.
13.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to accept the DC-248, 360 and 387 in Uncoated form as against Film Coated Tablet in the tender	DC-248, Each Film-coated tablet contain: Levocetirizine Dihydrochloride IP 5 mg DC-360, Each Film coated tablet contains: Mifepristone IP 200mg DC-387, Each Film coated tablet contains: Terbinafine Hydrochloride IP equivalent to Terbinafine 250mg	Tender condition prevails.
14.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to accept DC-325 in Tablet form as against Capsule in the tender	Fluoxetine Hydrochloride Capsules IP 20mg	Tender condition prevails.
15.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to allow DC-613 as Diclofenac Sodium as against Diclofenac Potassium in the tender	Each film-coated tablet contains: Diclofenac Potassium 50 mg Paracetamol 325 mg Serratiopeptidase 10mg (20,000 serratiopeptidase unit as enteric coated granules)	Tender condition prevails.
16.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to accept DC-648 in Gel form as against Spray in the tender	Composition: Diclofenac Diethylamine IP 1.16% Eq. to Diclofenac Sodium 1% w/w Linseed oil BP (Oleum Lini) 3% ww Methyle Salicylate IP 10% W/W Menthol IP 5% W/W Excipients & propellant q. s. to 100% w/w	Tender condition prevails.

17.	Annexure - XII Clause 18 (M) & BOQ	DC-748 Glimepiride Tablets IP 4mg	Each uncoated tablet contains Glibenclamide IP 4mg	Each uncoated tablet contains Glimepiride IP 4mg
18.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to change DC- 759 as Pack size 10x10 and unit size 10's	Each film coated tablet contains Rosuvastatin Calcium IP equivalent to Rosuvastatin 10mg Pack size 15'sx10 and unit size 15's	Tender condition prevails.
19.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to change DC- 1312 as Pack size 10x10 and unit size 10's	Each film coated tablet contains Flavoxate Hydrochloride IP 200 mg Pack size 15'sx10 and unit size 15's	Tender condition prevails.
20.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to change DC-665 in Tablet form as against Capsule in tender	Each soft gelatin capsule contains: Thiamine (vit. B1) 10mg Riboflavin (vit. B2) 10mg Niacinamide (vit. B3) 50mg Pyridoxine Hydrochloride (vit. B6) 3mg Cynocobalamine (vit. B12) 5mcg Calcium Pantothenate 12.5mg Folic acid 1mg Ascorbic acid (vitamin C) 150mg	Tender condition prevails.
21.	Annexure - XII Clause 18 (M) & BOQ	Prospective bidder has requested to relax market standing certificate for DC-580.	Specification as per tender document	Tender condition prevails.

All other contents of tender document remain unaltered. Prospective bidders are requested to quote their rates considering all the terms and condition of the tender document including Amendment no.1 dated 29/01/2021.

Sd/-
Manager (Procurement)
For & on behalf of BPPI
PH: 011-49431812